Sur cette page
01LXRX prix
02Aperçu
03Graphique
04Splits d'actions
05À propos
06Performance
07Valorisation et ratios
14Bénéfices
15Fondamentaux complets
16États financiers
17Détenteurs institutionnels (13F)
18Activistes et détenteurs de 5%+
19Initiés de la société
20Détention d'ETF
21Consensus
22Pairs
23Actualités
26Mes métriques
LXRX Lexicon Pharmaceuticals, Inc. - Common Stock
NASDAQ · Pharmaceuticals · Voir sur SEC EDGAR ↗ clôture Oct 2, 2026 10-K/10-Q Aoû 6, 2026
$1,82
· % de la fourchette 52 sem.
· au-dessus du plus bas
· vers le haut
$1,11Bas 52 semaines
$2,68Haut 52 semaines
Capitalisation Boursière (MRQ)
$813M
P/E (TTM)
-12.1
BPA (TTM)
$-0.15
Revenu (TTM)
$41M
vos badges
Fourchette 52 semaines
$1–$3
Note des analystes
BUY
Objectif de cours
$5
P/E
-12.1
ROE
-40.2%
Marge nette
-147.4%
Votre barre de badges est vide — épinglez une métrique n'importe où sur cette page.
LXRX Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines
Prix
$1.82
Capitalisation Boursière (MRQ)
$813M
P/E (TTM)
-12.1
BPA (TTM)
$-0.15
Revenu (TTM)
$41M
ROE (TTM)
-40.2%
Dette/Capitaux propres (MRQ)
0.3
Fourchette 52 semaines
$1–$3
LXRX Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue
fourchette
barres
La granularité des barres s'adapte à la période sélectionnée — survolez le graphique pour voir l'ouverture/le maximum/le minimum/la clôture d'une barre.
Splits d'actions
| Date ex-dividende | Division | Type |
|---|---|---|
| 21 mai 2015 | 1-for-7 | Inverse |
À propos de Lexicon Pharmaceuticals, Inc. - Common Stock Présentation de l'entreprise depuis Wikipedia
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
The company's clinical drug candidates include sotagliflozin (LX4211) for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl (LX1032) for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis.
Company history
Lexicon Pharmaceuticals was founded in September 1995 as a biotech venture of Baylor College of Medicine. The company went public in April 2000 with $220 million initial public offerings. In June, 2001 Lexicon purchased a privately owned small chemical library synthesis company, Coelacanth Corporation in Princeton, New Jersey, which became the site for the company's small molecule and medicinal chemistry efforts. The company's original name was Lexicon Genetics Incorporated, but in 2007, the name changed to Lexicon Pharmaceuticals, Inc. to reflect a renewed focus on drug development.
The company initially focused on using gene knockout technology to define the function of genes. This effort complemented and benefited from the international effort to sequence the human and mouse genomes (see Human Genome Project). Using its proprietary gene trapping and gene targeting technologies, the company created A repository of genetically modified mouse embryonic stem cells, known as OmniBank, and established a large-scale mammalian knockout program to discover the physiological and behavioral functions of the most druggable mammalian genes. The information collected from this program is stored in the company's LexVision database, which contains almost 5,000 gene knockouts studied. Over the years, Lexicon evolved from a genomics company into a drug discovery and development company focused on discovering and developing treatments for human disease. The company currently has multiple drug candidates in various stages of clinical trials.
In 2016, the company was ranked #8 on the Deloitte Fast 500 North America list.
Technology
Lexicon uses patented gene trapping and gene targeting technologies to generate and study knockout mice to discover the physiological and behavioral effects that result from the disruption of a single gene knockout. Because there is a close similarity in gene function and physiology between mice and humans, with a large majority of human genes having a counterpart in the mouse genome, knockout mouse technology has become a powerful tool in the discovery of new medicines.
The value of Lexicon's technology in drug discovery has been described in a retrospective analysis by the scientific journal Nature. The conclusion of this analysis was that, in most cases, there was a direct correlation when comparing the physiological characteristics, or phenotypes, of knockout mice to the therapeutic effect of the 100 best-selling drugs of 2001. The tremendous utility of knockout mouse technology was recognized in 2007 with the Nobel Prize in Physiology or Medicine to Drs. Mario Capecchi, Martin Evans, and Oliver Smithies.
In developing small molecule drugs for its validated targets, Lexicon uses medicinal chemistry known as "click chemistry." Dr. K. Barry Sharpless, who was awarded the 2001 Nobel Prize in Chemistry, developed this tools for the rapid synthesis of novel compounds. Lexicon uses solution-phase chemistry to generate diverse libraries of optically pure compounds that are built using organic reactions that allow the company to generate collections of different compounds and to tailor the compound collections to address various therapeutic target families. Lexicon's medicinal chemists design these libraries by analyzing the chemical structures of drugs that have been proven safe and effective against human disease and using that knowledge in the design of scaffolds and chemical building blocks for the generation of large numbers of new drug-like compounds.
Locations
Lexicon operates from two locations found in Texas and New Jersey. The corporate headquarters are in The Woodlands, Texas just north of Houston. This location serves as Lexicon's primary research facility to discover and validate the company's drug targets and test drug candidates in preclinical research. The company's clinical development and regulatory team is also based at the corporate headquarters.
Lexicon's campus in Princeton, New Jersey is the home of Lexicon's small molecule medicinal chemistry and preclinical development efforts. This site serves as Lexicon's primary medicinal chemistry site to create new chemical entities for therapeutic development.
== References ==
Source : Wikipedia (Anglais), CC BY-SA 4.0 · Voir sur Wikipedia ↗
secteurHealthcare
industriePharmaceuticals
employés81
paysUS
Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA
Revenu$50M2016-12-31 → 2025-12-31
BPA$-0.142017-12-31 → 2025-12-31
Flux de trésorerie libre$-68M2016-12-31 → 2025-12-31
Marge nette-147.4%2016-12-31 → 2025-12-31
Valorisation et Ratios
Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?
| Métrique | Tendance sur 5 ans | LXRX | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -12.1moyenne 5 ans ≈-4.2 | ≈-4.2 | · | · | |
| P/S (TTM) | 19.6moyenne 5 ans ≈1530.9 | ≈1530.9 | 6.6 | Surévalué | |
| P/B (MRQ) | 4.7moyenne 5 ans ≈4.1 | ≈4.1 | 3.8 | Surévalué | |
| EV / EBITDA (TTM) | -12.5 | · | · | · | |
| Price / FCF (Cours / FCF) | -9.8moyenne 5 ans ≈-5.6 | ≈-5.6 | · | · | |
| Price / Cash Flow (Cours / Flux de trésorerie) | -9.8moyenne 5 ans ≈-5.7 | ≈-5.7 | · | · | |
| VE / Chiffre d'affaires (TTM) | 16.3 | · | · | · | |
| EV / FCF (VE / FCF) | -9.2 | · | · | · | |
| Price / Tangible Book (Cours / Actif net tangible) | 10.6moyenne 5 ans ≈6.7 | ≈6.7 | · | · |
La médiane des pairs est calculée sur une base standardisée par métrique et peut ne pas toujours correspondre à la base TTM/MRQ indiquée pour cette action.
Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC
| Métrique | Tendance sur 5 ans | LXRX | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Marge d'exploitation (TTM) | -131.4%moyenne 5 ans ≈-23342.3% | ≈-23342.3% | -78.2% | Faible | |
| Marge EBITDA (TTM) | -130.3%moyenne 5 ans ≈-23251.5% | ≈-23251.5% | -59.5% | Faible | |
| Marge nette (TTM) | -147.4%moyenne 5 ans ≈-23649.3% | ≈-23649.3% | -23.7% | Faible | |
| ROA (TTM) | -25.7%moyenne 5 ans ≈-58.7% | ≈-58.7% | -34.1% | Premier rang | |
| ROE (TTM) | -40.2%moyenne 5 ans ≈-105.9% | ≈-105.9% | 50.0% | Faible |
Santé financière Dette, liquidité, solvabilité — solidité du bilan
| Métrique | Tendance sur 5 ans | LXRX | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Dette / Capitaux propres (MRQ) | 0.3moyenne 5 ans ≈0.6 | ≈0.6 | 0.0 | Endettement élevé | |
| Ratio de liquidité (MRQ) | 13.4moyenne 5 ans ≈5.2 | ≈5.2 | 4.3 | Liquidité solide | |
| Ratio de liquidité réduite (MRQ) | 13.1moyenne 5 ans ≈5.1 | ≈5.1 | 2.0 | Liquidité solide | |
| Dette à long terme / Capitaux propres (MRQ) | 0.3moyenne 5 ans ≈0.7 | ≈0.7 | 0.0 | Endettement élevé |
Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans
| Métrique | Tendance sur 5 ans | LXRX | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Revenue YoY (Chiffre d'affaires YoY) | 60.2%moyenne 5 ans ≈631.2% | ≈631.2% | · | · | |
| Revenue CAGR 3Y (CAGR du chiffre d'affaires 3 ans) | 610.2%moyenne 5 ans ≈305.9% | ≈305.9% | · | · | |
| Revenue CAGR 5Y (CAGR du chiffre d'affaires 5 ans) | 15.7% | · | · | · |
Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances
| Métrique | Tendance sur 5 ans | LXRX | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Asset Turnover (Rotation des actifs) | 0.2moyenne 5 ans ≈0.1 | ≈0.1 | 0.4 | Faible | |
| Inventory Turnover (Rotation des stocks) | 1.1moyenne 5 ans ≈1.2 | ≈1.2 | 2.1 | Faible | |
| Receivables Turnover (Rotation des créances) | 17.0moyenne 5 ans ≈8.3 | ≈8.3 | 3.5 | Premier rang | |
| Revenue / Employee (Chiffre d'affaires annuel ÷ employés (effectif déclaré, yfinance). Dérivé — pas un concept SEC-XBRL stocké.) | ≈$614.9K | · | · | · |
valeur · ≈ moyenne 5 ans · médiane du secteur · verdict par rapport à la médiane
Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats
Surprise Moyenne
48.2%
Prochain rapport
Nov 13, 2026
| Période | Rapport | EPS Actual | BPA est. | Surprise |
|---|---|---|---|---|
| 30 juin 2026 | Aoû 4, 2026 | $-0.07 | $-0.05 | -36.7% |
| 31 mars 2026 | Mai 11, 2026 | $0.00 | $-0.04 | 100.0% |
| 31 décembre 2025 | $-0.04 | $-0.07 | 43.2% | |
| 30 septembre 2025 | $-0.04 | $-0.07 | 40.6% | |
| 30 juin 2025 | $0.01 | $-0.08 | 112.6% | |
| 31 mars 2025 | $-0.07 | $-0.10 | 29.6% |
Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie
Compte de résultat
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50M | $31M | $1M | $139.0K | $298.0K | $24M | $322M | $63M | $92M | $79M | $130M | $23M | |
| Cost of Revenue | $274.0K | $616.0K | $85.0K | $0 | $0 | $2M | $3M | $2M | $2M | $0 | $0 | · | |
| R&D Expense | $61M | $84M | $59M | $53M | $55M | $154M | $92M | $100M | $152M | $164M | $95M | $89M | |
| SG&A Expense | $37M | $143M | $114M | $48M | $32M | $47M | $57M | $64M | $66M | $43M | $24M | $19M | |
| Operating Expenses | $99M | $228M | $173M | $101M | $87M | $204M | $181M | $166M | $222M | $206M | $129M | $123M | |
| Operating Income | $-49M | $-197M | $-172M | $-101M | $-87M | $-48M | $141M | $-103M | $-131M | $-127M | $1M | $-100M | |
| Interest Expense | · | · | · | $3M | $802.0K | $15M | $21M | $21M | $7M | $7M | $7M | $2M | |
| Other Non-op | $7M | $12M | $8M | $2M | $134.0K | $3M | $3M | $4M | $2M | $2M | $572.0K | $2M | |
| Pretax Income | · | · | · | · | $-88M | $-59M | $124M | $-121M | $-136M | $-131M | $-5M | $-100M | |
| Income Tax | · | $0 | $0 | $0 | $0 | · | · | · | · | $0 | $0 | $-70.0K | |
| Net Income | $-50M | $-200M | $-177M | $-102M | $-88M | $-59M | $130M | $-121M | $-123M | $-131M | $-5M | $-100M | |
| EPS (Basic) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.23 | $-1.14 | $-1.17 | · | · | · | |
| EPS (Diluted) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.16 | $-1.14 | $-1.17 | · | · | · | |
| Shares (Basic) | 363,053,000 | 320,031,000 | 221,130,000 | 165,733,000 | 145,652,000 | · | · | · | · | · | · | · | |
| Shares (Diluted) | 363,053,000 | 320,031,000 | 221,130,000 | 165,733,000 | 145,652,000 | 110,841,000 | 116,747,000 | 105,830,000 | 105,237,000 | · | · | · | |
| EBITDA | $-48M | $-197M | $-171M | $-100M | $-87M | $-45M | $145M | $-100M | $-133M | $-135M | · | $-98M |
Bilan
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $34M | $67M | $22M | $46M | $64M | $126M | $36M | $80M | $62M | $47M | $203M | $137M | |
| Short-term Investments | $62M | $171M | $148M | $92M | $23M | $26M | $236M | $80M | $249M | $300M | $318M | $202M | |
| Receivables | $2M | $3M | $1M | $28.0K | $14.0K | $395.0K | $57M | $6M | $5M | $7M | $911.0K | $1M | |
| Inventory | $281.0K | $231.0K | $381.0K | $0 | · | $0 | $4M | $5M | $2M | $0 | · | · | |
| Other Current Assets | $3M | $5M | $5M | $2M | $2M | $5M | $5M | $3M | $4M | $4M | $10M | $5M | |
| Current Assets | $102M | $246M | $177M | $141M | $89M | $158M | $338M | $173M | $322M | $358M | $532M | $369M | |
| PP&E (Net) | $2M | $2M | $2M | $2M | $1M | $295.0K | $14M | $16M | $18M | $19M | $21M | $1M | |
| PP&E (Gross) | $5M | $5M | $7M | $6M | $6M | $6M | $76M | $76M | $76M | $79M | $81M | $37M | |
| Accum. Depreciation | $3M | $2M | $5M | $4M | $5M | $6M | $62M | $60M | $59M | $60M | $59M | $36M | |
| Goodwill | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | |
| Intangibles | · | · | · | · | · | · | $20M | $50M | $52M | $53M | $53M | $53M | |
| Other Non-current Assets | $368.0K | $368.0K | $828.0K | $412.0K | $2M | $1M | $2M | $285.0K | $429.0K | $461.0K | $433.0K | $3M | |
| Total Assets | $185M | $298M | $229M | $194M | $137M | $204M | $418M | $284M | $437M | $476M | $652M | $471M | |
| Accounts Payable | $3M | $15M | $14M | $10M | $9M | $5M | $12M | $12M | $39M | $53M | $20M | $13M | |
| Accrued Liabilities | $13M | $30M | $17M | $13M | $13M | $30M | $42M | $21M | $12M | $32M | $25M | $10M | |
| Current Liabilities | $21M | $45M | $32M | $23M | $22M | $47M | $65M | $37M | $105M | $165M | $123M | $45M | |
| Capital Leases | $7M | $5M | $5M | $5M | · | · | · | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $0 | $6M | $6M | $19M | $19M | $19M | |
| Other Non-current Liabilities | $7M | $7M | $5M | $5M | $1M | $611.0K | $1M | $238.0K | $292.0K | $805.0K | $14M | $24M | |
| Total Liabilities | $77M | $152M | $136M | $77M | $23M | $47M | $301M | $311M | $368M | $318M | $366M | $187M | |
| Long-term Debt | $54M | $100M | · | $49M | $0 | $12M | $249M | $250M | $252M | $101M | $106M | $108M | |
| Total Debt | $54M | $100M | $100M | · | $0 | $12M | $245M | $245M | $246M | $101M | · | $108M | |
| Common Stock | $366.0K | $363.0K | $245.0K | $189.0K | $150.0K | $142.0K | $106.0K | $106.0K | $106.0K | $105.0K | $104.0K | $104.0K | |
| Paid-in Capital | $2.13B | $2.12B | $1.86B | $1.71B | $1.61B | $1.56B | $1.46B | $1.45B | $1.44B | $1.41B | $1.40B | $1.39B | |
| Retained Earnings | $-2.02B | $-1.97B | $-1.77B | $-1.59B | $-1.49B | $-1.40B | $-1.34B | $-1.47B | $-1.37B | $-1.25B | $-1.11B | $-1.10B | |
| Treasury Stock | $5M | $5M | $3M | $2M | $8M | $5M | $4M | $3M | $2M | $3M | $3M | $2M | |
| AOCI | $30.0K | $119.0K | $31.0K | $-428.0K | $-10.0K | $-6.0K | $84.0K | $-12.0K | $-222.0K | $-195.0K | $-219.0K | $-63.0K | |
| Stockholders' Equity | $108M | $146M | $93M | $117M | $114M | $156M | $117M | $-26M | $68M | $168M | $286M | $284M | |
| Liabilities + Equity | $185M | $298M | $229M | $194M | $137M | $204M | $418M | $284M | $437M | $476M | $652M | $471M | |
| Shares Outstanding | 365,848,216 | 363,020,303 | · | 189,214,000 | 150,082,000 | 142,289,000 | 106,679,000 | 106,162,000 | 105,711,000 | 104,582,000 | 103,860,000 | 103,663,000 |
Flux de trésorerie
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $621.0K | $534.0K | $554.0K | $427.0K | $292.0K | $3M | $4M | $4M | $3M | $2M | $727.0K | $2M | |
| Stock-based Comp | $13M | $13M | $14M | $12M | $11M | $13M | $14M | $12M | $9M | $7M | $7M | $7M | |
| Deferred Tax | · | · | · | $0 | $0 | $0 | $-6M | $0 | $-13M | $0 | $0 | $-70.0K | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $2M | $2M | · | · | · | |
| Other Non-cash | $-31M | $8M | $328.0K | $1M | $-10M | $-101M | $-28M | $-43M | $-57M | $-44M | · | $16M | |
| Operating Cash Flow | $-68M | $-179M | $-162M | $-89M | $-87M | $-143M | $114M | $-149M | $-185M | $-176M | $185M | $-76M | |
| CapEx | $0 | $1M | $470.0K | $1M | $1M | $87.0K | $70.0K | $95.0K | $228.0K | $231.0K | $910.0K | $80.0K | |
| Investing Cash Flow | $113M | $-15M | $-50M | $-71M | $2M | $381M | $-156M | $170M | $51M | $18M | $-117M | $-108M | |
| Debt Issued | $0 | $0 | $50M | $49M | · | $0 | $0 | $13M | $146M | $0 | $0 | $84M | |
| Net Debt Issued | $0 | $0 | · | $49M | $-12M | $-217M | $-1M | $-2M | $144M | $-2M | · | $82M | |
| Stock Issued | $0 | $0 | $139M | $94M | $37M | $70M | $0 | $732.0K | $8M | $4M | $114.0K | $202M | |
| Stock Repurchased | · | $2M | $824.0K | $864.0K | $3M | $1M | $941.0K | $972.0K | $2M | $621.0K | $357.0K | $887.0K | |
| Net Stock Activity | $0 | $-2M | $138M | $93M | $34M | $69M | $-941.0K | $-240.0K | $6M | $3M | · | $201M | |
| Financing Cash Flow | $-48M | $238M | $188M | $142M | $23M | $-148M | $-2M | $-2M | $150M | $987.0K | $-2M | $284M | |
| Net Change in Cash | $-3M | $44M | $-24M | $-18M | $-62M | $90M | $-44M | $19M | $15M | $-156M | $66M | $100M | |
| Free Cash Flow | $-68M | $-180M | $-162M | $-90M | $-88M | $-143M | $114M | $-149M | $-186M | $-176M | · | $-76M | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-182M | · | $-78M |
Rentabilité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -98.2% | -634.2% | -14264.9% | -72489.2% | -29224.8% | -199.2% | 43.9% | -163.4% | -151.3% | -164.6% | · | -439.2% | |
| Net Margin | -101.1% | -644.8% | -14710.9% | -73341.0% | -29449.0% | -244.1% | 40.4% | -190.7% | -142.9% | -169.7% | · | -438.8% | |
| Pretax Margin | · | · | · | · | -29449.0% | -244.1% | 38.5% | -190.7% | -156.9% | -169.7% | · | -439.1% | |
| EBITDA Margin | -97.0% | -632.5% | -14218.9% | -72182.0% | -29126.9% | -187.0% | 45.1% | -157.6% | -147.5% | -162.1% | · | -430.7% | |
| ROA | -20.8% | -75.9% | -83.6% | -61.6% | -51.5% | -18.9% | 37.1% | -33.5% | -28.3% | -25.1% | · | -26.9% | |
| ROE | -39.7% | -167.7% | -168.5% | -88.4% | -65.0% | -42.8% | 287.0% | -576.0% | -117.5% | -63.8% | · | -44.2% | |
| ROIC | · | · | · | · | · | · | · | · | · | -53.0% | · | -25.6% |
Liquidité et Solvabilité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.9 | 5.4 | 5.6 | 6.1 | 4.0 | 3.4 | 5.2 | 4.7 | 2.6 | 2.2 | · | 8.2 | |
| Quick Ratio | 4.7 | 5.3 | 5.4 | 6.0 | 3.9 | 3.3 | 5.0 | 4.5 | 2.5 | 2.2 | · | 7.6 | |
| Debt / Equity | 0.5 | 0.7 | 1.1 | · | 0.0 | 0.1 | 2.1 | -9.3 | 4.7 | 0.6 | · | 0.4 | |
| LT Debt / Equity | 0.5 | 0.7 | 1.1 | · | · | 0.0 | 2.0 | -9.2 | 4.4 | 0.5 | · | 0.3 | |
| Interest Coverage | · | · | · | -36.2 | -108.6 | -3.3 | 6.8 | -5.0 | -19.6 | -20.9 | · | -44.5 |
Efficacité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.9 | 0.2 | 0.2 | 0.1 | · | 0.1 | |
| Inventory Turnover | 1.1 | 2.0 | 0.4 | · | · | 0.9 | 0.7 | 0.8 | 1.9 | · | · | · | |
| Receivables Turnover | 17.0 | 13.9 | 2.3 | 6.6 | 1.5 | 0.8 | 10.3 | 11.8 | 14.7 | 19.8 | · | 25.0 |
Par action
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.29 | · | · | $0.62 | $0.76 | $1.10 | $1.10 | $-0.25 | $0.49 | $1.50 | · | $0.39 | |
| Revenue / Share | $0.14 | $0.10 | $0.01 | · | $0.00 | $0.22 | $2.76 | · | · | · | · | · | |
| Cash Flow / Share | $-0.19 | $-0.56 | $-0.73 | · | $-0.60 | $-1.29 | $0.97 | · | · | · | · | · | |
| Cash / Share | $0.09 | · | · | $0.24 | $0.43 | $0.89 | $0.34 | $0.76 | $0.58 | $0.45 | · | $0.19 | |
| EPS (TTM) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.16 | $-1.14 | $-1.17 | $-0.12 | $-0.12 | · |
Taux de croissance
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 60.2% | 2481.5% | 766.2% | -53.4% | -98.8% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 610.2% | 370.7% | -63.1% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.7% | · | · | · | · | · | · | · | · | · | · | · |
Valorisation (TTM)
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $50M | $31M | $1M | $139.0K | $298.0K | $24M | $322M | $63M | $92M | $79M | $130M | $23M | |
| Net Income TTM | $-50M | $-200M | $-177M | $-102M | $-88M | $-59M | $130M | $-121M | $-123M | $-131M | $-5M | $-100M | |
| Market Cap | $421M | · | · | $361M | $591M | $487M | $443M | $705M | $1.04B | $1.45B | · | $4.62B | |
| Enterprise Value | $378M | · | · | · | $505M | $346M | $416M | $790M | $979M | $1.20B | · | $4.39B | |
| P/E | -8.2 | -1.2 | -1.9 | -3.1 | -6.6 | -6.5 | 3.6 | -5.8 | -8.4 | -115.2 | -110.9 | · | |
| P/S | 8.4 | · | · | 2600.0 | 1984.3 | 20.3 | 1.4 | 11.2 | 11.4 | 18.2 | · | 202.3 | |
| P/B | 3.9 | · | · | 3.1 | 5.2 | 3.1 | 3.8 | -26.7 | 20.0 | 9.2 | · | 16.3 | |
| P / Tangible Book | 6.7 | · | · | 5.0 | 8.6 | 4.4 | · | · | · | · | · | · | |
| P / Cash Flow | -6.2 | · | · | -4.1 | -6.8 | -3.4 | 3.9 | -4.7 | -5.6 | -8.2 | · | -61.1 | |
| P / FCF | -6.2 | · | · | -4.0 | -6.7 | -3.4 | 3.9 | -4.7 | -5.6 | -8.2 | · | -61.1 | |
| EV / EBITDA | -7.8 | · | · | · | -5.8 | -7.7 | 2.9 | -7.9 | -7.3 | -8.9 | · | -44.6 | |
| EV / FCF | -5.6 | · | · | · | -5.7 | -2.4 | 3.7 | -5.3 | -5.3 | -6.8 | · | -58.0 | |
| EV / Revenue | 7.6 | · | · | · | 1693.2 | 14.4 | 1.3 | 12.5 | 10.7 | 15.2 | · | 192.1 | |
| Earnings Yield | -12.2% | -85.1% | -52.3% | -32.5% | -15.2% | -15.5% | 28.0% | -17.2% | -11.8% | -0.87% | -0.90% | · |
Compte de résultat
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $692.0K | $21M | $5M | $14M | $29M | $1M | $27M | $2M | $2M | $1M | $701.0K | $162.0K | $317.0K | $24.0K | $28.0K | $39.0K | |
| Cost of Revenue | $39.0K | $108.0K | $201.0K | $10.0K | $33.0K | $30.0K | $348.0K | $71.0K | $166.0K | $31.0K | $70.0K | $7.0K | $8.0K | $0 | $0 | $0 | |
| R&D Expense | $17M | $13M | $11M | $19M | $16M | $15M | $27M | $26M | $18M | $14M | $15M | $18M | $15M | $12M | $14M | $11M | |
| SG&A Expense | $10M | $9M | $9M | $8M | $9M | $12M | $32M | $40M | $39M | $32M | $33M | $32M | $30M | $19M | $16M | $13M | |
| Operating Expenses | $27M | $22M | $20M | $26M | $25M | $27M | $59M | $65M | $57M | $46M | $47M | $50M | $45M | $31M | $30M | $23M | |
| Operating Income | $-27M | $-996.0K | $-15M | $-12M | $4M | $-26M | $-33M | $-64M | $-55M | $-45M | $-47M | $-50M | $-44M | $-31M | $-30M | $-23M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | · | · | $4M | $2M | $2M | · | $864.0K | |
| Other Non-op | $2M | $2M | $1M | $2M | $2M | $2M | $3M | $3M | $4M | $2M | $2M | $3M | $1M | $1M | $887.0K | $572.0K | |
| Net Income | $-32M | $-1M | $-16M | $-13M | $3M | $-25M | $-34M | $-65M | $-53M | $-48M | $-50M | $-51M | $-45M | $-32M | $-30M | $-23M | |
| EPS (Basic) | $-0.07 | $0.00 | $-0.04 | $-0.04 | $0.01 | $-0.07 | $-0.08 | $-0.18 | $-0.17 | $-0.20 | $-0.20 | $-0.21 | $-0.22 | $-0.17 | $-0.17 | $-0.13 | |
| EPS (Diluted) | $-0.07 | $0.00 | $-0.04 | $-0.04 | $0.01 | $-0.07 | $-0.08 | $-0.18 | $-0.17 | $-0.20 | $-0.20 | $-0.21 | $-0.22 | $-0.17 | $-0.17 | $-0.13 | |
| Shares (Basic) | 437,653,000 | 400,240,000 | · | 363,399,000 | 363,294,000 | 362,073,000 | · | 361,492,000 | 310,836,000 | 245,390,000 | · | 244,925,000 | 204,783,000 | 189,014,000 | · | 174,904,000 | |
| Shares (Diluted) | 437,653,000 | 400,240,000 | · | 363,399,000 | 363,570,000 | 362,073,000 | · | 361,492,000 | 310,836,000 | 245,390,000 | · | 244,925,000 | 204,783,000 | 189,014,000 | · | 174,904,000 | |
| EBITDA | $-27M | $-886.0K | · | $-12M | $4M | · | · | $-64M | $-55M | $-45M | · | $-50M | · | $-31M | · | $-23M |
Bilan
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $41M | $38M | $34M | $50M | $21M | $63M | $67M | $35M | $36M | $96M | · | $21M | $102M | $26M | · | $19M | |
| Short-term Investments | $150M | $133M | $62M | $66M | $118M | $132M | $171M | $224M | $274M | $259M | · | $197M | $154M | $80M | · | $117M | |
| Receivables | $2M | $12M | $2M | $2M | $2M | $47M | $3M | $3M | $3M | $2M | · | $318.0K | $685.0K | $261.0K | · | $39.0K | |
| Inventory | $1M | $276.0K | $281.0K | $158.0K | $168.0K | $201.0K | $231.0K | $636.0K | $585.0K | $514.0K | · | $336.0K | $172.0K | · | · | · | |
| Other Current Assets | $3M | $3M | $3M | $4M | $4M | $3M | $5M | $7M | $8M | $7M | · | $4M | $6M | $3M | · | $3M | |
| Current Assets | $197M | $186M | $102M | $123M | $145M | $246M | $246M | $269M | $321M | $365M | · | $223M | $264M | $110M | · | $139M | |
| PP&E (Net) | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $932.0K | |
| PP&E (Gross) | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | · | · | · | · | · | · | · | |
| Accum. Depreciation | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $5M | · | $4M | $4M | $4M | · | $5M | |
| Goodwill | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | · | $45M | $45M | $45M | · | $45M | |
| Other Non-current Assets | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $828.0K | $828.0K | $828.0K | · | $743.0K | $6M | $6M | · | $7M | |
| Total Assets | $250M | $269M | $185M | $206M | $226M | $298M | $298M | $321M | $373M | $417M | · | $276M | $317M | $163M | · | $192M | |
| Accounts Payable | $2M | $3M | $3M | $4M | $6M | $11M | $15M | $14M | $12M | $8M | · | $12M | $11M | $10M | · | $9M | |
| Accrued Liabilities | $12M | $7M | $13M | $14M | $11M | $13M | $30M | $22M | $16M | $15M | · | $20M | $16M | $10M | · | $9M | |
| Current Liabilities | $15M | $10M | $21M | $22M | $35M | $111M | $45M | $36M | $28M | $23M | · | $32M | $26M | $20M | · | $18M | |
| Capital Leases | $6M | $6M | $7M | $7M | $4M | $4M | $5M | $5M | $5M | $5M | · | $5M | · | · | · | · | |
| Other Non-current Liabilities | $9M | $6M | $7M | $8M | $5M | $5M | $7M | $7M | $6M | · | · | · | $5M | $5M | · | $5M | |
| Total Liabilities | $76M | $66M | $77M | $86M | $96M | $175M | $152M | $143M | $133M | $128M | · | $137M | $130M | $75M | · | $48M | |
| Long-term Debt | $51M | $50M | $54M | · | · | $101M | $100M | · | · | · | · | $99M | $99M | $49M | · | $24M | |
| Total Debt | $51M | $50M | · | $57M | $56M | · | · | $100M | $99M | $100M | · | $99M | · | $49M | · | $24M | |
| Common Stock | $447.0K | $426.0K | $366.0K | $366.0K | $366.0K | $366.0K | $363.0K | $363.0K | $363.0K | $248.0K | · | $245.0K | $245.0K | $190.0K | · | $189.0K | |
| Paid-in Capital | $2.23B | $2.22B | $2.13B | $2.13B | $2.12B | $2.12B | $2.12B | $2.12B | $2.11B | $2.11B | · | $1.86B | $1.86B | $1.71B | · | $1.71B | |
| Retained Earnings | $-2.05B | $-2.02B | $-2.02B | $-2.00B | $-1.99B | $-1.99B | $-1.97B | $-1.93B | $-1.87B | $-1.82B | · | $-1.72B | $-1.67B | $-1.62B | · | $-1.56B | |
| Treasury Stock | $3M | $3M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | · | $3M | $3M | $3M | · | $2M | |
| AOCI | $-204.0K | $-130.0K | $30.0K | $29.0K | $-14.0K | $25.0K | $119.0K | $349.0K | $-193.0K | $-50.0K | · | $-113.0K | $-100.0K | $-163.0K | · | $-491.0K | |
| Stockholders' Equity | $175M | $203M | $108M | $120M | $129M | $123M | $146M | $179M | $240M | $289M | · | $140M | $186M | $88M | · | $144M | |
| Liabilities + Equity | $250M | $269M | $185M | $206M | $226M | $298M | $298M | $321M | $373M | $417M | · | $276M | $317M | $163M | · | $192M | |
| Shares Outstanding | 446,870,629 | 425,708,402 | 365,848,216 | 365,780,799 | · | · | 363,020,303 | · | · | · | · | · | · | · | · | · |
Flux de trésorerie
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $102.0K | $110.0K | $118.0K | $151.0K | $176.0K | $176.0K | $125.0K | $126.0K | $139.0K | $144.0K | $147.0K | $151.0K | $144.0K | $112.0K | $103.0K | $108.0K | |
| Stock-based Comp | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $3M | $5M | $4M | $3M | $4M | $4M | $3M | $3M | $3M | |
| Other Non-cash | · | $-17M | · | · | · | · | · | · | · | $-11M | · | · | · | $-3M | · | · | |
| Operating Cash Flow | $-9M | $-15M | $-17M | $-24M | $17M | $-44M | $-21M | $-54M | $-49M | $-55M | $-51M | $-42M | $-38M | $-32M | $-22M | $-19M | |
| CapEx | · | · | $0 | $0 | · | · | $474.0K | $307.0K | $250.0K | $0 | $0 | $83.0K | $139.0K | $248.0K | $1M | $4.0K | |
| Investing Cash Flow | $-16M | $-70M | $5M | $52M | $15M | $41M | $54M | $53M | $-12M | $-110M | $52M | $-39M | $-75M | $12M | $24M | $-77M | |
| Debt Issued | · | · | · | · | · | · | $0 | $0 | · | · | $-1.0K | $1.0K | $50M | $0 | $25M | $-249.0K | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Stock Issued | $791.0K | $70M | · | · | $0 | $0 | $0 | $0 | $-88.0K | $88.0K | $0 | $-211.0K | $139M | $0 | $-63.0K | $94M | |
| Stock Repurchased | · | · | · | · | · | · | · | $0 | $0 | $2M | · | $0 | $0 | $824.0K | $0 | $0 | |
| Net Stock Activity | · | $70M | · | · | · | · | · | · | · | $-2M | · | · | · | $-824.0K | · | · | |
| Financing Cash Flow | $-512.0K | $89M | $-3M | $0 | $-45M | $-572.0K | $-104.0K | $-916.0K | $-14.0K | $239M | $-1.0K | $-210.0K | $189M | $-824.0K | $25M | $94M | |
| Net Change in Cash | $-26M | $4M | $-15M | $28M | $-13M | $-4M | $32M | $-1M | $-61M | $74M | $1M | $-81M | $76M | $-20M | $28M | $-3M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-55M | · | · | · | $-32M | · | · |
Rentabilité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -3835.3% | -4.7% | · | -85.9% | 12.9% | · | · | -3639.6% | -3360.9% | -4011.8% | · | -30636.4% | · | · | · | · | |
| Net Margin | -4591.8% | -4.9% | · | -90.0% | 11.3% | · | · | -3703.5% | -3244.0% | -4282.9% | · | -31188.3% | · | · | · | · | |
| EBITDA Margin | -3835.3% | -4.2% | · | -85.9% | 12.9% | · | · | -3639.6% | -3360.9% | -3999.0% | · | -30636.4% | · | · | · | · | |
| ROA | -13.4% | -0.37% | · | -4.9% | 1.1% | · | · | -21.7% | -15.5% | -16.7% | · | -21.6% | · | -21.4% | · | -12.8% | |
| ROE | -20.9% | -0.64% | · | -8.6% | 1.8% | · | · | -40.8% | -25.1% | -25.7% | · | -35.6% | · | -35.3% | · | -16.7% |
Liquidité et Solvabilité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.4 | 18.8 | · | 5.6 | 4.2 | · | · | 7.5 | 11.5 | 15.6 | · | 6.9 | · | 5.4 | · | 7.5 | |
| Quick Ratio | 13.1 | 18.4 | · | 5.4 | 4.1 | · | · | 7.2 | 11.2 | 15.3 | · | 6.8 | · | 5.2 | · | 7.4 | |
| Debt / Equity | 0.3 | 0.2 | · | 0.5 | 0.4 | · | · | 0.6 | 0.4 | 0.3 | · | 0.7 | · | 0.6 | · | 0.2 | |
| LT Debt / Equity | 0.3 | 0.2 | · | 0.5 | 0.4 | · | · | 0.6 | 0.4 | 0.3 | · | 0.7 | · | 0.6 | · | 0.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | · | · | -12.7 | · | -17.1 | · | -26.7 |
Efficacité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.1 | 0.1 | · | · | 0.0 | 0.0 | 0.0 | · | 0.0 | · | · | · | · | |
| Inventory Turnover | 0.1 | 0.5 | · | 0.0 | 0.1 | · | · | 0.1 | 0.4 | 0.0 | · | 0.0 | · | · | · | · | |
| Receivables Turnover | 0.4 | 0.7 | · | 5.4 | 12.0 | · | · | 1.1 | 1.0 | 1.3 | · | 0.9 | · | · | · | · |
Par action
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.39 | $0.48 | · | $0.33 | · | · | · | · | · | · | · | · | · | · | · | · | |
| Revenue / Share | $0.00 | $0.05 | · | $0.04 | $0.08 | · | · | $0.00 | $0.01 | $0.00 | · | $0.00 | · | · | · | · | |
| Cash Flow / Share | · | $-0.04 | · | · | · | · | · | · | · | $-0.22 | · | · | · | · | · | · | |
| Cash / Share | $0.09 | $0.09 | · | $0.14 | · | · | · | · | · | · | · | · | · | · | · | · | |
| EPS (TTM) | $-0.15 | $-0.07 | · | $-0.18 | $-0.32 | $-0.50 | · | $-0.75 | $-0.78 | $-0.83 | · | $-0.77 | $-0.69 | · | · | · |
Valorisation (TTM)
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $41M | $70M | · | $71M | $58M | $31M | · | $5M | $4M | $2M | · | $531.0K | $408.0K | $126.0K | · | · | |
| Net Income TTM | $-61M | $-26M | · | $-69M | $-121M | $-177M | · | $-216M | $-202M | $-194M | · | $-158M | $-131M | $-110M | · | $-97M | |
| Market Cap | $1.07B | $664M | · | $494M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Enterprise Value | $933M | $543M | · | $434M | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | -16.0 | -22.3 | · | -7.5 | -3.0 | -0.9 | · | -2.1 | -2.2 | -2.9 | · | -1.4 | -3.3 | · | · | · | |
| P/S | 25.9 | 9.5 | · | 7.0 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/B | 6.1 | 3.3 | · | 4.1 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Tangible Book | 8.3 | 4.2 | · | 6.5 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | -45.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 22.5 | 7.8 | · | 6.1 | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -6.2% | -4.5% | · | -13.3% | -33.7% | -108.7% | · | -47.8% | -46.4% | -34.6% | · | -70.6% | -30.1% | · | · | · |
Période la plus récente à gauche · valeurs nulles affichées comme ·
États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenu | $50M | $31M | $1M | $139.0K | $298.0K |
| Marge d'exploitation % | -98.2% | -634.2% | -14264.9% | -72489.2% | -29224.8% |
| Résultat net | $-50M | $-200M | $-177M | $-102M | $-88M |
| BPA dilué | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 |
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dette / Capitaux propres | 0.5 | 0.7 | 1.1 | · | 0.0 |
| Ratio de liquidité | 4.9 | 5.4 | 5.6 | 6.1 | 4.0 |
| Ratio de liquidité réduite | 4.7 | 5.3 | 5.4 | 6.0 | 3.9 |
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flux de trésorerie libre | $-68M | $-180M | $-162M | $-90M | $-88M |
Détenteurs institutionnels (13F) 167 déclarants · $890.0M total · Au 30 juin 2026
Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.
Détenteurs
167
Valeur détenue
$890.0M
Nouvelles positions
43
Positions clôturées
27
Activité institutionnelle — Q2 2026 vs trimestre précédent
| Nouvelles positions | Positions clôturées | Augmenté | Diminué | Variation nette des actions |
|---|---|---|---|---|
| 43 (+9 vs T. préc.) | 27 (+14 vs T. préc.) | 39 (-5 vs T. préc.) | 38 (+14 vs T. préc.) | +42.4M |
Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée.
| Institution | Valeur | Actions | % de 13F suivies | Type |
|---|---|---|---|---|
| Artal Group S.A. | $420 374 549 | 175 156 062 | 47,23% | Actions |
| FMR LLC | $124 276 907 | 51 782 045 | 13,96% | Actions |
| Siren, L.L.C. | $106 328 443 | 44 303 518 | 11,95% | Actions |
| Sessa Capital IM, L.P. | $45 506 006 | 18 960 836 | 5,11% | Actions |
| BlackRock, Inc. | $41 636 978 | 17 348 741 | 4,68% | Actions |
| VANGUARD CAPITAL MANAGEMENT LLC | $23 762 899 | 9 901 208 | 2,67% | Actions |
| Point72 Asset Management, L.P. | $19 803 180 | 8 251 325 | 2,23% | Actions |
| GEODE CAPITAL MANAGEMENT, LLC | $14 989 739 | 6 244 372 | 1,68% | Actions |
| STATE STREET CORP | $11 802 646 | 4 917 769 | 1,33% | Actions |
| VANGUARD GROUP INC | $11 047 532 | 9 606 549 | 1,24% | Actions |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $5 658 598 | 2 357 749 | 0,64% | Actions |
| NORTHERN TRUST CORP | $4 724 686 | 1 968 619 | 0,53% | Actions |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $4 696 260 | 1 956 775 | 0,53% | Actions |
| VANGUARD FIDUCIARY TRUST CO | $3 922 970 | 1 634 571 | 0,44% | Actions |
| CITADEL ADVISORS LLC | $3 842 837 | 1 601 182 | 0,43% | Actions |
| CIBC Private Wealth Group LLC | $3 240 347 | 2 400 257 | 0,36% | Actions |
| Ishara Investments LP | $3 050 400 | 1 271 000 | 0,34% | Actions |
| MILLENNIUM MANAGEMENT LLC | $2 722 150 | 1 134 229 | 0,31% | Actions |
| RENAISSANCE TECHNOLOGIES LLC | $2 704 800 | 1 127 000 | 0,30% | Actions |
| MACKENZIE FINANCIAL CORP | $2 312 050 | 963 354 | 0,26% | Actions |
| ADAR1 Capital Management, LLC | $1 800 000 | 750 000 | 0,20% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1 672 262 | 696 776 | 0,19% | Actions |
| UBS Group AG | $1 643 312 | 684 713 | 0,18% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1 604 400 | 668 500 | 0,18% | Option d'achat |
| TWO SIGMA INVESTMENTS, LP | $1 544 266 | 643 444 | 0,17% | Actions |
| Nuveen, LLC | $1 407 994 | 586 664 | 0,16% | Actions |
| JANE STREET GROUP, LLC | $1 398 960 | 582 900 | 0,16% | Option d'achat |
| Bank of New York Mellon Corp | $1 364 893 | 568 706 | 0,15% | Actions |
| Invesco Ltd. | $1 219 370 | 508 071 | 0,14% | Actions |
| GOLDMAN SACHS GROUP INC | $1 165 310 | 485 546 | 0,13% | Actions |
| Compagnie Lombard Odier SCmA | $1 152 000 | 480 000 | 0,13% | Actions |
| BANK OF AMERICA CORP /DE/ | $1 011 117 | 421 299 | 0,11% | Actions |
| BARCLAYS PLC | $929 960 | 387 483 | 0,10% | Actions |
| CITADEL ADVISORS LLC | $886 320 | 369 300 | 0,10% | Option d'achat |
| XTX Topco Ltd | $858 905 | 357 877 | 0,10% | Actions |
| CANADA PENSION PLAN INVESTMENT BOARD | $618 960 | 257 900 | 0,07% | Actions |
| RHUMBLINE ADVISERS | $616 523 | 256 885 | 0,07% | Actions |
| DEUTSCHE BANK AG\ | $594 068 | 247 528 | 0,07% | Actions |
| WELLS FARGO & COMPANY/MN | $553 128 | 230 470 | 0,06% | Actions |
| WELLINGTON MANAGEMENT GROUP LLP | $431 280 | 179 700 | 0,05% | Actions |
| CITIGROUP INC | $420 492 | 175 205 | 0,05% | Actions |
| GROUP ONE TRADING LLC | $420 031 | 175 013 | 0,05% | Actions |
| Virtus Investment Advisers, LLC | $408 996 | 170 415 | 0,05% | Actions |
| Headlands Technologies LLC | $401 275 | 167 198 | 0,05% | Actions |
| Ikarian Capital, LLC | $395 218 | 164 674 | 0,04% | Actions |
| Quarry LP | $374 846 | 156 186 | 0,04% | Actions |
| MetLife Investment Management, LLC | $351 384 | 146 410 | 0,04% | Actions |
| MORGAN STANLEY | $318 964 | 132 902 | 0,04% | Actions |
| PANAGORA ASSET MANAGEMENT INC | $316 901 | 132 042 | 0,04% | Actions |
| JPMORGAN CHASE & CO | $289 975 | 109 839 | 0,03% | Actions |
Activistes et détenteurs de 5%+ 11 participations
Investisseurs ayant déposé un Schedule 13D auprès de la SEC — détention effective supérieure à 5% avec l'intention d'influencer l'émetteur (participations activistes, campagnes pour le conseil d'administration, fusions-acquisitions). Chaque ligne montre le dernier état connu de la position du déposant.
| Déclarant | Déposé | Participation | Statut | Objectif | Dépôt |
|---|---|---|---|---|---|
| Invus, L.P., Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., Avicenna Life Sci Master Fund LP, Avicenna Life Sci Master GP LLC, Invus US Partners LLC, Ulys, L.L.C., Raymond Debbane, Artal Participations S.a r.l., Artal International S.C.A., Artal International Management S.A., Artal Group S.A., Westend S.A., Stichting Administratiekantoor Westend, Amaury Wittouck ×7 dépôts | 8 mai 2026 | 39,40% | Amendement | · | SEC |
| Invus, L.P. (2), Invus Advisors, L.L.C. (2), Invus Public Equities, L.P. (2), Invus Public Equities Advisors, LLC (2), Invus Global Management, LLC (2), Siren, L.L.C. (2), Artal Participations S.à r.l. (2), Artal International S.C.A. (2), Artal International Management S.A. (2), Artal Group S.A. (2), Westend S.A. (2), Stichting Administratiekantoor Westend (2), Mr. Amaury Wittouck (2), Invus US Partners LLC (2), Ulys, L.L.C. (2), Mr. Raymond Debbane (2) ×15 dépôts | 9 décembre 2024 | · | Dépôt initial | · | SEC |
| 24 février 2012 | · | Dépôt initial | · | SEC | |
| Raymond Debbane (2), Ulys, L.L.C. (2), Invus Advisors, L.L.C. (2), Invus, L.P. (2), Invus Public Equities Advisors, LLC (2), Invus Public Equities, L.P. (2), Invus C.V. (2) | 27 décembre 2011 | · | Dépôt initial | · | SEC |
| 14 novembre 2011 | · | Dépôt initial | · | SEC | |
| 15 août 2011 | · | Dépôt initial | · | SEC | |
| Raymond Debbane, Ulys, L.L.C., Invus Advisors, L.L.C., Invus, L.P., Invus Public Equities Advisors, LLC, Invus Public Equities, L.P., Invus C.V. | 19 mars 2010 | · | Dépôt initial | Structure du capital | SEC |
| Estate of Gordon A. Cain (, Mary H. Cain ×4 dépôts | 5 août 2005 | · | Dépôt initial | · | SEC |
| Personne déclarante non divulguée, Personne déclarante non divulguée, Personne déclarante non divulguée | 8 août 2003 | · | Dépôt initial | · | SEC |
| Personne déclarante non divulguée, Personne déclarante non divulguée, Personne déclarante non divulguée | 18 juillet 2003 | · | Dépôt initial | Investissement passif | SEC |
| Personne déclarante non divulguée, Personne déclarante non divulguée, Personne déclarante non divulguée, Personne déclarante non divulguée | 19 mars 2003 | · | Dépôt initial | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Initiés de la société 49 initiés · 32 dirigeants · 19 administrateurs
| Dirigeant | Rôle | Dernière activité | Actions détenues | Achats 12m | Ventes 12m | Net 12m |
|---|---|---|---|---|---|---|
| Michael Exton | Chief Executive Officer | 28 février 2026 M | 298 432 | 0 | 0 | $0 |
| Lonnel Coats | Chief Executive Officer | 28 février 2024 M | 1 098 068 | 0 | 0 | $0 |
| Arthur T Sands | President & CEO | 28 février 2014 M | 1 021 329 | 0 | 0 | $0 |
| Scott M Coiante | SVP, Chief Financial Officer | 28 février 2026 M | 105 356 | 0 | 0 | $0 |
| Ajay Bansal | EVP Corp Dev and CFO | 2 juin 2009 A | · | 0 | 0 | $0 |
| Julia P Gregory | EVP and CFO | 7 février 2008 A | 50 200 | 0 | 0 | $0 |
| Jeffrey L Wade | President and COO | 8 juillet 2024 A | 324 214 | 0 | 0 | $0 |
| Rachel Yap Martens | SVP, Partnerships & Corp Strat | 28 février 2026 M | 31 264 | 0 | 0 | $0 |
| Suma Gopinathan | SVP, Discovery | 28 février 2026 M | 150 132 | 0 | 0 | $0 |
| Wendy Mcdermott | SVP, Human Resources | 28 février 2026 M | 277 945 | 0 | 0 | $0 |
| Craig B Granowitz | SVP, Chief Medical Officer | 28 février 2026 M | 323 430 | 0 | 0 | $0 |
| Lisa Defrancesco | SVP, IR and Corp Comm | 28 février 2026 M | 93 869 | 0 | 0 | $0 |
| Brian T Crum | SVP, General Counsel & Secr. | 28 février 2026 M | 428 802 | 0 | 0 | $0 |
| Kristen Alexander | VP, Finance and Accounting | 28 février 2025 M | 76 368 | 0 | 0 | $0 |
| Alan J Main | EVP, Innov & Chem Sciences | 28 février 2025 M | 339 104 | 0 | 0 | $0 |
| Brian Corrigan | SVP, Regulatory & QA | 13 février 2025 A | · | 0 | 0 | $0 |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | 28 février 2024 M | 162 672 | 0 | 0 | $0 |
| Thomas Garner | SVP, Chief Commercial Officer | 8 février 2024 A | · | 0 | 0 | $0 |
| Kiernan Seth | VP, Chief Commercial Officer | 28 février 2023 M | 53 136 | 0 | 0 | $0 |
| James F Tessmer | VP, Finance & Accounting | 15 mars 2021 M | 71 766 | 0 | 0 | $0 |
| Alexander A Santini | EVP and CCO | 22 avril 2020 F | 55 584 | 0 | 0 | $0 |
| Pablo Lapuerta | EVP and CMO | 22 avril 2020 F | 85 719 | 0 | 0 | $0 |
| John Northcott | VP, Marketing, Comm Strategy | 2 mars 2015 M | 8 235 | 0 | 0 | $0 |
| Brian P Zambrowicz | EVP, Chief Scientific Officer | 28 février 2014 M | 278 703 | 0 | 0 | $0 |
| Steven Alan Tragash | VP, Corporate Affairs | 15 février 2010 A | · | 0 | 0 | $0 |
| Philip M Brown | SVP, Clinical Development | 15 février 2010 A | 27 306 | 0 | 0 | $0 |
| James R Piggott PHD | SVP of Pharm Bio | 7 février 2008 A | 0 | 0 | 0 | $0 |
| Lance K Ishimoto | SVP, Intellectual Property | 7 février 2008 A | 10 200 | 0 | 0 | $0 |
| Tamar D Howson | EVP of Bus Dev | 7 février 2008 A | · | 0 | 0 | $0 |
| Walter F Colbert | SVP, HR and Corp Serv | 13 février 2007 A | · | 0 | 0 | $0 |
| Randall B Riggs | SVP, Corp Licensing | 23 février 2004 M | 15 000 | 0 | 0 | $0 |
| Christophe Person | VP Informatics | 12 janvier 2004 M | 0 | 0 | 0 | $0 |
| Ivan Cheung | Administrateur | 3 juin 2026 M | 89 312 | 0 | 0 | $0 |
| Diane E. Sullivan | Administrateur | 3 juin 2026 M | 126 122 | 0 | 0 | $0 |
| Judith L Swain | Administrateur | 3 juin 2026 M | 174 486 | 0 | 0 | $0 |
| Amouyal Philippe | Administrateur | 3 juin 2026 M | 374 486 | 0 | 0 | $0 |
| Sam L Barker | Administrateur | 3 juin 2026 M | 213 771 | 0 | 0 | $0 |
| Christopher J Sobecki | Administrateur | 3 juin 2026 M | 293 177 | 0 | 0 | $0 |
| Raymond Debbane | Administrateur | 3 juin 2026 M | 1 995 498 | 7 | 0 | $723 048 |
| Robert J Lefkowitz MD | Administrateur | 13 mai 2024 A | 48 364 | 0 | 0 | $0 |
| Frank Palantoni | Administrateur | 21 mai 2023 M | 40 332 | 0 | 0 | $0 |
| Alan S Nies | Administrateur | 21 mai 2023 M | 41 046 | 0 | 0 | $0 |
| Invus C.V. | Administrateur | 31 décembre 2020 J | 0 | 0 | 0 | $0 |
| Kathleen M Wiltsey | Administrateur | 24 avril 2009 A | · | 0 | 0 | $0 |
| Clayton Stuart Rose | Administrateur | 26 juin 2007 P | 25 000 | 0 | 0 | $0 |
| Barry Mills | Administrateur | 26 avril 2007 A | 25 000 | 0 | 0 | $0 |
| Patricia M Cloherty | Administrateur | 27 avril 2006 A | · | 0 | 0 | $0 |
| Thomas C Caskey | Administrateur | 13 octobre 2005 P | 6 300 | 0 | 0 | $0 |
| Praveen Tyle | · | 28 février 2021 M | 120 791 | 0 | 0 | $0 |
Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché
Détention d'ETF Détenu par 16 ETFs
Le poids reflète uniquement les participations directes en actions (N-PORT) ; les fonds à effet de levier ou basés sur des dérivés peuvent détenir une exposition supplémentaire aux swaps non indiquée.
| Fonds | Poids | Unités | Au | Source |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0,81% | 161 882 NS | 31 juillet 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 0,45% | 40 310 NS | 31 juillet 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,42% | 53 319 SH | 2 octobre 2026 | Quotidien |
| IWC · iShares Trust | 0,12% | 842 323 SH | 11 septembre 2026 | Quotidien |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,04% | 266 401 SH | 19 août 2026 | Quotidien |
| IWO · iShares Trust | 0,03% | 2 343 443 SH | 11 septembre 2026 | Quotidien |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 1 432 882 SH | 19 août 2026 | Quotidien |
| RSSL · Global X Funds | 0,02% | 118 391 NS | 31 juillet 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,02% | 255 130 SH | 2 octobre 2026 | Quotidien |
| IWM · iShares Trust | 0,02% | 6 319 224 SH | 11 septembre 2026 | Quotidien |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 2 594 934 SH | 19 août 2026 | Quotidien |
| VHT · VANGUARD WORLD FUND | 0,01% | 637 561 SH | 19 août 2026 | Quotidien |
| WSML · iShares Trust | 0,01% | 17 992 SH | 11 septembre 2026 | Quotidien |
| IWV · iShares Trust | 0,00% | 85 389 SH | 3 septembre 2026 | Quotidien |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 7 083 651 SH | 19 août 2026 | Quotidien |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 20 905 SH | 19 août 2026 | Quotidien |
LXRX Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse
notation · 11 analystes
ACHAT
Objectif médian
$4.55
+150,0%
3 27,3%
Achat fort
5 45,5%
Achat
3 27,3%
Conserver
0 0,0%
Vente
0 0,0%
Vente forte
Objectif de cours à 12 mois
6 analystes · 2026-09-30Objectif moyen $4.55 +149,8%
← En dessous de tous les objectifs
Prix actuel $1.82
Bas$2.00
Moyenne$4.55
Haut$8.00
Comparaison des pairs (sous-secteur GICS) Indicateurs clés par rapport aux pairs du secteur
Base F.A., prix à la clôture de la dernière fin d'exercice de chaque société.
| Ticker | Capitalisation Boursière | P/E | Revenus Année/Année | Marge Nette | ROE | Marge Brute |
|---|---|---|---|---|---|---|
| LXRX | $421M | -8.2 | 60.2% | -101.1% | -39.7% | · |
| ANRO | $568M | -8.1 | · | · | -46.1% | · |
| ALMS | · | -3.4 | · | -1011.8% | -61.9% | · |
| APMD | · | · | · | · | · | · |
| SGP | · | · | · | · | 50.0% | · |
| COLL | $1.47B | 26.8 | 23.6% | 8.1% | 23.5% | 59.4% |
| ACRS | $363M | -5.7 | -58.2% | -829.6% | -55.3% | · |
| ZVRA | $509M | 6.6 | 350.9% | 78.2% | 61.2% | · |
| AQST | $788M | -8.3 | -22.6% | -188.1% | 157.7% | · |
| PHAT | $1.18B | -5.5 | 216.9% | -126.4% | 52.4% | 87.1% |
Dernières actualités Actualités récentes mentionnant cette entreprise
Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets
Choisissez les indicateurs qui vous importent — cliquez sur le + à côté de n'importe quelle ligne dans les Fondamentaux complets ci-dessus.
Votre sélection est enregistrée et vous suit sur tous les tickers.
Source : Dépôt SEC 10-Q le Aoû 6, 2026